Massimiliano Ruscica

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2488489/publications.pdf

Version: 2024-02-01

211 papers

6,191 citations

43 h-index 65 g-index

223 all docs

223
docs citations

times ranked

223

8711 citing authors

#	Article	IF	CITATIONS
1	Lactate Buildup at the Site of Chronic Inflammation Promotes Disease by Inducing CD4+ T Cell Metabolic Rewiring. Cell Metabolism, 2019, 30, 1055-1074.e8.	7.2	266
2	Monocyteâ€toâ€HDLâ€cholesterol ratio as a prognostic marker in cardiovascular diseases. Journal of Cellular Physiology, 2018, 233, 9237-9246.	2.0	169
3	PCSK9 induces a pro-inflammatory response in macrophages. Scientific Reports, 2018, 8, 2267.	1.6	166
4	PPAR Agonists and Metabolic Syndrome: An Established Role?. International Journal of Molecular Sciences, 2018, 19, 1197.	1.8	165
5	Dietary Iron Overload Induces Visceral Adipose Tissue Insulin Resistance. American Journal of Pathology, 2013, 182, 2254-2263.	1.9	128
6	PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor. European Heart Journal, 2019, 40, 357-368.	1.0	124
7	Liver fat accumulation is associated with circulating PCSK9. Annals of Medicine, 2016, 48, 384-391.	1.5	119
8	The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM \hat{l}_{\pm}) paradigm: conceptual framework and therapeutic potential. Cardiovascular Diabetology, 2019, 18, 71.	2.7	104
9	Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line. Journal of Biological Chemistry, 2016, 291, 3508-3519.	1.6	93
10	Pharmacokinetics of orally administered melatonin in critically ill patients. Journal of Pineal Research, 2010, 48, 142-147.	3.4	88
11	Molecular Aspects of Adipokine-Bone Interactions. Current Molecular Medicine, 2010, 10, 522-532.	0.6	88
12	Efficacy and Safety of Mipomersen: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Drugs, 2019, 79, 751-766.	4.9	86
13	The natural antioxidant alpha-lipoic acid induces p27Kip1-dependent cell cycle arrest and apoptosis in MCF-7 human breast cancer cells. European Journal of Pharmacology, 2010, 641, 29-34.	1.7	82
14	PCSK9 inhibition and inflammation: A narrative review. Atherosclerosis, 2019, 288, 146-155.	0.4	80
15	PCSK9 knock-out mice are protected from neointimal formation in response to perivascular carotid collar placement. Atherosclerosis, 2016, 253, 214-224.	0.4	78
16	GC–MS profiling of the phytochemical constituents of the oleoresin from Copaifera langsdorffii Desf. and a preliminary in vivo evaluation of its antipsoriatic effect. International Journal of Pharmaceutics, 2013, 440, 170-178.	2.6	76
17	The impact of type of dietary protein, animal versus vegetable, in modifying cardiometabolic risk factors: A position paper from the International Lipid Expert Panel (ILEP). Clinical Nutrition, 2021, 40, 255-276.	2.3	7 5
18	Nutraceutical approach to moderate cardiometabolic risk: Results of a randomized, double-blind and crossover study with Armolipid Plus. Journal of Clinical Lipidology, 2014, 8, 61-68.	0.6	74

#	Article	IF	CITATIONS
19	Effect of Fenretinide and Low-Dose Tamoxifen on Insulin Sensitivity in Premenopausal Women at High Risk for Breast Cancer. Cancer Research, 2008, 68, 9512-9518.	0.4	72
20	Parthenolide Inhibits the LPSâ€induced Secretion of ILâ€6 and TNFâ€Î± and NFâ€ÎB Nuclear Translocation in BV†Microglia. Phytotherapy Research, 2012, 26, 1405-1409.	€ ? 2.8	70
21	A new dawn for managing dyslipidemias: The era of rna-based therapies. Pharmacological Research, 2019, 150, 104413.	3.1	70
22	Activation of the Y1 Receptor by Neuropeptide Y Regulates the Growth of Prostate Cancer Cells. Endocrinology, 2006, 147, 1466-1473.	1.4	69
23	Risk identification and possible countermeasures for muscle adverse effects during statin therapy. European Journal of Internal Medicine, 2015, 26, 82-88.	1.0	67
24	Circulating Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and Arterial Stiffness in a Large Population Sample: Data From the Brisighella Heart Study. Journal of the American Heart Association, 2017, 6, .	1.6	66
25	Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels – experimental and clinical approaches with lipid-lowering agents. European Journal of Preventive Cardiology, 2019, 26, 930-949.	0.8	64
26	A mutation and expression analysis of the oncogene BRAF in pituitary adenomas. Clinical Endocrinology, 2007, 66, 348-352.	1.2	63
27	Prognostic Effect of Circulating Adiponectin in a Randomized 2 \tilde{A} — 2 Trial of Low-Dose Tamoxifen and Fenretinide in Premenopausal Women at Risk for Breast Cancer. Journal of Clinical Oncology, 2012, 30, 151-157.	0.8	63
28	Free and bound plasma leptin in normal weight and obese men and women: relationship with body composition, resting energy expenditure, insulin-sensitivity, lipid profile and macronutrient preference. Clinical Endocrinology, 2005, 62, 189-196.	1.2	62
29	The i148m Pnpla3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls. BMC Gastroenterology, 2012, 12, 111.	0.8	62
30	Unravelling the health effects of fasting: a long road from obesity treatment to healthy life span increase and improved cognition. Annals of Medicine, 2020, 52, 147-161.	1.5	62
31	Proprotein Convertase Subtilisin/Kexin Type 9. American Journal of Pathology, 2021, 191, 1385-1397.	1.9	62
32	PCSK9 as a PositiveÂModulator of Platelet Activation. Journal of the American College of Cardiology, 2018, 71, 952-954.	1.2	60
33	Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia. Endocrine, 2016, 54, 588-601.	1.1	58
34	Side effects of statins: from pathophysiology and epidemiology to diagnostic and therapeutic implications. Cardiovascular Research, 2023, 118, 3288-3304.	1.8	57
35	Clinical approach to the inflammatory etiology of cardiovascular diseases. Pharmacological Research, 2020, 159, 104916.	3.1	56
36	Altered Cytokine and Acute Phase Response Protein Levels in the Blood of Children with Downs Syndrome: Relationship with Dementia of Alzheimer's Type. International Journal of Immunopathology and Pharmacology, 2005, 18, 165-172.	1.0	54

#	Article	IF	CITATIONS
37	Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: New therapeutic approaches for the treatment of atherogenic dyslipidemia. Pharmacological Research, 2020, 153, 104653.	3.1	54
38	Translating the biology of adipokines in atherosclerosis and cardiovascular diseases: Gaps and open questions. Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, 379-395.	1.1	52
39	Menstrual and reproductive history and use of exogenous sex hormones and risk of thyroid cancer among women: a meta-analysis of prospective studies. Cancer Causes and Control, 2015, 26, 511-518.	0.8	51
40	Effect of soy on metabolic syndrome and cardiovascular risk factors: a randomized controlled trial. European Journal of Nutrition, 2018, 57, 499-511.	1.8	49
41	MicroRNAs: Novel Molecular Targets and Response Modulators of Statin Therapy. Trends in Pharmacological Sciences, 2018, 39, 967-981.	4.0	48
42	Increased PCSK9 Cerebrospinal Fluid Concentrations in Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 55, 315-320.	1.2	47
43	Statin therapy and related risk of new-onset type 2 diabetes mellitus. European Journal of Internal Medicine, 2014, 25, 401-406.	1.0	45
44	Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence. Translational Research, 2016, 173, 19-29.	2.2	45
45	Present therapeutic role of cholesteryl ester transfer protein inhibitors. Pharmacological Research, 2018, 128, 29-41.	3.1	45
46	Relevance of the Neuropeptide Y System in the Biology of Cancer Progression. Current Topics in Medicinal Chemistry, 2007, 7, 1682-1691.	1.0	44
47	Feeding Behavior in Mammals Including Humans. Annals of the New York Academy of Sciences, 2009, 1163, 221-232.	1.8	44
48	PPAR-α agonists are still on the rise: an update on clinical and experimental findings. Expert Opinion on Investigational Drugs, 2017, 26, 593-602.	1.9	44
49	Statins and C-reactive protein: in silico evidence on direct interaction. Archives of Medical Science, 2020, 16, 1432-1439.	0.4	44
50	TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in InÂVitro Models. Cellular and Molecular Gastroenterology and Hepatology, 2022, 13, 759-788.	2.3	44
51	Is ghrelin a signal of decreased fat-free mass in elderly subjects?. European Journal of Endocrinology, 2006, 155, 321-330.	1.9	43
52	Impaired expression of insulinâ€like growth factorâ€1 system in skeletal muscle of amyotrophic lateral sclerosis patients. Muscle and Nerve, 2012, 45, 200-208.	1.0	43
53	Appropriateness of statin prescription in the elderly. European Journal of Internal Medicine, 2018, 50, 33-40.	1.0	43
54	Proprotein Convertase Subtilisin/Kexin Type 9, Brain Cholesterol Homeostasis and Potential Implication for Alzheimer's Disease. Frontiers in Aging Neuroscience, 2019, 11, 120.	1.7	43

#	Article	IF	CITATIONS
55	Naturally Occurring PCSK9 Inhibitors. Nutrients, 2020, 12, 1440.	1.7	43
56	The liaison between respiratory failure and high blood pressure: evidence from COVID-19 patients. European Respiratory Journal, 2020, 56, 2001157.	3.1	43
57	Fibronectin Type III Domain–Containing Protein 5 rs3480 A>G Polymorphism, Irisin, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2660-2669.	1.8	42
58	PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients. Journal of Lipid Research, 2019, 60, 1144-1153.	2.0	42
59	Resveratrol and cognitive decline: a clinician perspective. Archives of Medical Science, 2019, 15, 936-943.	0.4	41
60	Ceramides and diabetes mellitus: an update on the potential molecular relationships. Diabetic Medicine, 2020, 37, 11-19.	1.2	41
61	Lipid Lowering Drugs: Present Status and Future Developments. Current Atherosclerosis Reports, 2021, 23, 17.	2.0	41
62	Antioxidant Effects of Statins by Modulating Nrf2 and Nrf2/HO-1 Signaling in Different Diseases. Journal of Clinical Medicine, 2022, 11, 1313.	1.0	40
63	Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases – A position paper from the International Lipid Expert Panel (ILEP). Progress in Cardiovascular Diseases, 2021, 67, 40-52.	1.6	39
64	Lipoprotein(a): Knowns, unknowns and uncertainties. Pharmacological Research, 2021, 173, 105812.	3.1	39
65	Leukemia Inhibitory Factor Induces the Chemomigration of Immortalized Gonadotropin-Releasing Hormone Neurons through the Independent Activation of the Janus Kinase/Signal Transducer and Activator of Transcription 3, Mitogen-Activated Protein Kinase/Extracellularly Regulated Kinase 1/2, and Phosphatidylinositol 3-Kinase/Akt Signaling Pathways, Molecular Endocrinology, 2007, 21, 1163-1174.	3.7	37
66	Nutraceutical approach for the management of cardiovascular risk $\hat{a} \in \hat{a}$ a combination containing the probiotic Bifidobacterium longum BB536 and red yeast rice extract: results from a randomized, double-blind, placebo-controlled study. Nutrition Journal, 2019, 18, 13.	1.5	37
67	ETC-1002 (Bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials. Expert Opinion on Pharmacotherapy, 2019, 20, 791-803.	0.9	37
68	Long-term exposure to air pollution raises circulating levels of proprotein convertase subtilisin/kexin type 9 in obese individuals. European Journal of Preventive Cardiology, 2019, 26, 578-588.	0.8	36
69	The effect of statin therapy on endoplasmic reticulum stress. Pharmacological Research, 2018, 137, 150-158.	3.1	35
70	Low-intermediate dose testosterone replacement therapy by different pharmaceutical preparations improves frailty score in elderly hypogonadal hyperglycaemic patients. Aging Male, 2013, 16, 33-37.	0.9	33
71	Leptin, Ciliary Neurotrophic Factor, Leukemia Inhibitory Factor and Interleukin- 6: Class-I Cytokines Involved in the Neuroendocrine Regulation of the Reproductive Function. Current Protein and Peptide Science, 2009, 10, 577-584.	0.7	32
72	Nonalcoholic fatty liver disease or metabolic dysfunctionâ€associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches. European Journal of Clinical Investigation, 2021, 51, e13519.	1.7	32

#	Article	IF	CITATIONS
73	Depression and cardiovascular risk—association among Beck Depression Inventory, PCSK9 levels and insulin resistance. Cardiovascular Diabetology, 2020, 19, 187.	2.7	31
74	Prognostic parameters of inâ€hospital mortality in COVIDâ€19 patientsâ€"An Italian experience. European Journal of Clinical Investigation, 2021, 51, e13629.	1.7	31
75	Somatostatin and dopamine receptor interaction in prostate and lung cancer cell lines. Journal of Endocrinology, 2010, 207, 309-317.	1.2	29
76	Sex-specific predictors of PCSK9 levels in a European population: The IMPROVE study. Atherosclerosis, 2020, 309, 39-46.	0.4	29
77	Lipid lowering drugs and inflammatory changes: an impact on cardiovascular outcomes?. Annals of Medicine, 2018, 50, 461-484.	1.5	28
78	Src and phosphoâ€FAK kinases are activated by allopregnanolone promoting Schwann cell motility, morphology and myelination. Journal of Neurochemistry, 2017, 141, 165-178.	2.1	27
79	Somatostatin, Somatostatin Analogs and Somatostatin Receptor Dynamics in the Biology of Cancer Progression. Current Molecular Medicine, 2013, 13, 555-571.	0.6	27
80	HDL therapy today: from atherosclerosis, to stent compatibility to heart failure. Annals of Medicine, 2019, 51, 345-359.	1.5	26
81	Leptin, Resistin, and Proprotein Convertase Subtilisin/Kexin Type 9. American Journal of Pathology, 2020, 190, 2226-2236.	1.9	26
82	Cardiovascular risk and testosterone – from subclinical atherosclerosis to lipoprotein function to heart failure. Reviews in Endocrine and Metabolic Disorders, 2021, 22, 257-274.	2.6	26
83	Role of neuropeptide Y and its receptors in the progression of endocrine-related cancer. Peptides, 2007, 28, 426-434.	1.2	25
84	High Density Lipoproteins Inhibit Oxidative Stress-Induced Prostate Cancer Cell Proliferation. Scientific Reports, 2018, 8, 2236.	1.6	25
85	Cholesteryl ester transfer protein: An enigmatic pharmacology – Antagonists and agonists. Atherosclerosis, 2018, 278, 286-298.	0.4	25
86	Regulation of prostate cancer cell proliferation by somatostatin receptor activation. Molecular and Cellular Endocrinology, 2010, 315, 254-262.	1.6	24
87	Hepatic steatosis and <scp>PNPLA</scp> 3 I148 <scp>M</scp> variant are associated with serum <scp>F</scp> etuinâ€ <scp>A</scp> independently of insulin resistance. European Journal of Clinical Investigation, 2014, 44, 627-633.	1.7	24
88	Theranostic Nanocages for Imaging and Photothermal Therapy of Prostate Cancer Cells by Active Targeting of Neuropeptide-Y Receptor. Bioconjugate Chemistry, 2016, 27, 2911-2922.	1.8	24
89	Nutraceutical approaches to metabolic syndrome. Annals of Medicine, 2017, 49, 678-697.	1.5	24
90	Recent advances in synthetic pharmacotherapies for dyslipidaemias. European Journal of Preventive Cardiology, 2020, 27, 1576-1596.	0.8	24

#	Article	IF	CITATIONS
91	Effects of a lupin protein concentrate on lipids, blood pressure and insulin resistance in moderately dyslipidaemic patients: A randomised controlled trial. Journal of Functional Foods, 2017, 37, 8-15.	1.6	22
92	Reduction of Cardio-Metabolic Risk and Body Weight through a Multiphasic Very-Low Calorie Ketogenic Diet Program in Women with Overweight/Obesity: A Study in a Real-World Setting. Nutrients, 2021, 13, 1804.	1.7	22
93	High-Density Lipoprotein Function Is Reduced in Patients Affected by Genetic or Idiopathic Hypogonadism. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3097-3107.	1.8	21
94	Lipoprotein(a) Lowering—From Lipoprotein Apheresis to Antisense Oligonucleotide Approach. Journal of Clinical Medicine, 2020, 9, 2103.	1.0	21
95	Bococizumab for the treatment of hypercholesterolaemia. Expert Opinion on Biological Therapy, 2017, 17, 237-243.	1.4	20
96	Body composition and metabolic changes during a 520-day mission simulation to Mars. Journal of Endocrinological Investigation, 2018, 41, 1267-1273.	1.8	20
97	Serum irisin is upregulated in patients affected by amyotrophic lateral sclerosis and correlates with functional and metabolic status. Journal of Neurology, 2018, 265, 3001-3008.	1.8	20
98	Lipoprotein(a) and PCSK9 inhibition: clinical evidence. European Heart Journal Supplements, 2020, 22, L53-L56.	0.0	20
99	Free insulinâ€like growth factor (IGF)â€1 and IGFâ€binding proteinsâ€2 and â€3 in serum and cerebrospinal fluid of amyotrophic lateral sclerosis patients. European Journal of Neurology, 2010, 17, 398-404.	1.7	19
100	Non-insulin anti-diabetic drugs: An update on pharmacological interactions. Pharmacological Research, 2017, 115, 14-24.	3.1	19
101	Effect of statin therapy on plasma apolipoprotein CIII concentrations: A systematic review and meta-analysis of randomized controlled trials. Journal of Clinical Lipidology, 2018, 12, 801-809.	0.6	19
102	From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients. European Journal of Preventive Cardiology, 2018, 25, 1843-1851.	0.8	19
103	PCSK9 Levels Are Raised in Chronic HCV Patients with Hepatocellular Carcinoma. Journal of Clinical Medicine, 2020, 9, 3134.	1.0	19
104	Long-term fasting improves lipoprotein-associated atherogenic risk in humans. European Journal of Nutrition, 2021, 60, 4031-4044.	1.8	19
105	Pulse wave velocity as a measure of arterial stiffness in patients with familial hypercholesterolemia: a systematic review and meta-analysis. Archives of Medical Science, 2019, 15, 1365-1374.	0.4	18
106	Low Lipoprotein(a) Levels Predict Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Hepatology Communications, 2022, 6, 535-549.	2.0	18
107	The Efficacy of the Mineralcorticoid Receptor Antagonist Canrenone in COVID-19 Patients. Journal of Clinical Medicine, 2020, 9, 2943.	1.0	17
108	Statin therapy in athletes and patients performing regular intense exercise – Position paper from the International Lipid Expert Panel (ILEP). Pharmacological Research, 2020, 155, 104719.	3.1	17

#	Article	IF	CITATIONS
109	The effect of transgender hormonal treatment on high density lipoprotein cholesterol efflux capacity. Atherosclerosis, 2021, 323, 44-53.	0.4	17
110	Modulatory Actions of Neuropeptide Y on Prostate Cancer Growth: Role of MAP Kinase/ERK 1/2 Activatio. Advances in Experimental Medicine and Biology, 2007, 604, 96-100.	0.8	17
111	Free and bound plasma leptin in anorexia nervosa patients during a refeeding program. Endocrine, 2016, 51, 380-383.	1.1	16
112	Iron overload induces hypogonadism in male mice via extrahypothalamic mechanisms. Molecular and Cellular Endocrinology, 2017, 454, 135-145.	1.6	16
113	Differential effects of red yeast rice, Berberis aristata and Morus alba extracts on PCSK9 and LDL uptake. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 1245-1253.	1.1	16
114	BDNF Val66Met polymorphism alters food intake and hypothalamic BDNF expression in mice. Journal of Cellular Physiology, 2020, 235, 9667-9675.	2.0	16
115	PCSK9 Expression in Epicardial Adipose Tissue: Molecular Association with Local Tissue Inflammation. Mediators of Inflammation, 2020, 2020, 1-8.	1.4	16
116	Antiproliferative activity on human prostate carcinoma cell lines of new peptidomimetics containing the spiroazepinoindolinone scaffold. Bioorganic and Medicinal Chemistry, 2013, 21, 5470-5479.	1.4	15
117	Characterization and sub-cellular localization of SS1R, SS2R, and SS5R in human late-stage prostate cancer cells: Effect of mono- and bi-specific somatostatin analogs on cell growth. Molecular and Cellular Endocrinology, 2014, 382, 860-870.	1.6	15
118	Changes in Stress Hormones and Metabolism During a 105-Day Simulated Mars Mission. Aviation, Space, and Environmental Medicine, 2014, 85, 793-797.	0.6	15
119	PCSK9 antagonists and inflammation. Atherosclerosis, 2018, 268, 235-236.	0.4	15
120	Adipokine actions on cartilage homeostasis. Advances in Clinical Chemistry, 2011, 55, 61-79.	1.8	14
121	Plasma PCSK9 levels and lipoprotein distribution are preserved in carriers of genetic HDL disorders. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2018, 1863, 991-997.	1.2	14
122	Impact of PPAR-Alpha Polymorphismsâ€"The Case of Metabolic Disorders and Atherosclerosis. International Journal of Molecular Sciences, 2019, 20, 4378.	1.8	14
123	SARS-CoV-2 infection among asymptomatic homebound subjects in Milan, Italy. European Journal of Internal Medicine, 2020, 78, 161-163.	1.0	14
124	PCSK9 promotes arterial medial calcification. Atherosclerosis, 2022, 346, 86-97.	0.4	14
125	The Role of High-Density Lipoprotein Cholesterol in 2022. Current Atherosclerosis Reports, 2022, 24, 365-377.	2.0	14
126	Free and bound leptin in prepubertal children with Down's syndrome and different degrees of adiposity. European Journal of Clinical Nutrition, 2004, 58, 1547-1549.	1.3	13

#	Article	IF	CITATIONS
127	Expression of Functional Ciliary Neurotrophic Factor Receptors in Immortalized Gonadotrophin-Releasing Hormone-Secreting Neurones. Journal of Neuroendocrinology, 2005, 17, 286-291.	1.2	13
128	Metabolic Syndrome, Adipokines and Hormonal Factors in Pharmacologically Untreated Adult Elderly Subjects from the Brisighella Heart Study Historical Cohort. Obesity Facts, 2012, 5, 319-326.	1.6	13
129	Unsaponifiable Fraction of Unripe Fruits of Olea europaea: An Interesting Source of Anti-inflammatory Constituents. Planta Medica, 2016, 82, 273-278.	0.7	13
130	Effects of PM Exposure on the Methylation of Clock Genes in A Population of Subjects with Overweight or Obesity. International Journal of Environmental Research and Public Health, 2021, 18, 1122.	1.2	13
131	Omega-3 and cardiovascular prevention – Is this still a choice?. Pharmacological Research, 2022, 182, 106342.	3.1	13
132	Adiponectin Interactions in Bone and Cartilage Biology and Disease. Vitamins and Hormones, 2012, 90, 321-339.	0.7	12
133	Angiopoietin-like 3 and subclinical peripheral arterial disease: Evidence from the Brisighella Heart Study. European Journal of Preventive Cardiology, 2020, 27, 2251-2254.	0.8	12
134	Monocarboxylate transporter 1 deficiency impacts CD8+ T lymphocytes proliferation and recruitment to adipose tissue during obesity. IScience, 2022, 25, 104435.	1.9	12
135	Adipokines and Sexual Hormones Associated with the Components of the Metabolic Syndrome in Pharmacologically Untreated Subjects: Data from the Brisighella Heart Study. International Journal of Endocrinology, 2011, 2011, 1-6.	0.6	11
136	PCSK9 monoclonal antibodies and lipoprotein apheresis for lowering lipoprotein(a): making choices in an era of RNA-based therapies. European Journal of Preventive Cardiology, 2019, 26, 998-1000.	0.8	11
137	Methotrexate for Cardiovascular Risk Reduction: The Right Choice?. Angiology, 2020, 71, 105-107.	0.8	11
138	Associations Among PCSK9 Levels, Atherosclerosis-Derived Extracellular Vesicles, and Their miRNA Content in Adults With Obesity. Frontiers in Cardiovascular Medicine, 2021, 8, 785250.	1.1	11
139	Plasma adiponectin and leptin concentrations in professional rugby players. Journal of Biological Regulators and Homeostatic Agents, 2010, 24, 87-91.	0.7	10
140	Effect of Bariatric Surgery on Flow-Mediated Vasodilation as a Measure of Endothelial Function: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2022, 11, 4054.	1.0	10
141	Contribution of binge eating behaviour to cardiometabolic risk factors in subjects starting a weight loss or maintenance programme. British Journal of Nutrition, 2016, 116, 1984-1992.	1.2	9
142	Proprotein convertase subtilisin/kexin type 9: an update on the cardiovascular outcome studies. European Heart Journal Supplements, 2020, 22, E64-E67.	0.0	9
143	Influence of body variables in the development of metabolic syndromeâ€"A long term follow-up study. PLoS ONE, 2018, 13, e0192751.	1.1	9
144	Sex hormones and adipokines in healthy pre-menopausal, post-menopausal and elderly women, and in age-matched men: data from the Brisighella Heart study. Journal of Endocrinological Investigation, 2011, 34, e158-62.	1.8	9

#	Article	IF	Citations
145	HDL in COVID-19 Patients: Evidence from an Italian Cross-Sectional Study. Journal of Clinical Medicine, 2021, 10, 5955.	1.0	9
146	Impact of Soy \hat{I}^2 -Conglycinin Peptides on PCSK9 Protein Expression in HepG2 Cells. Nutrients, 2022, 14, 193.	1.7	9
147	Total, free and bound leptin and thyroid function in elderly women with different body weights. Clinical Endocrinology, 2008, 68, 1002-1008.	1.2	8
148	Deciphering the role of V200A and N291S mutations leading to LPL deficiency. Atherosclerosis, 2019, 282, 45-51.	0.4	8
149	Maternal exposure to air pollutants, PCSK9 levels, fetal growth and gestational age – An Italian cohort. Environment International, 2021, 149, 106163.	4.8	8
150	Hypothalamic Neuropeptide Systems as Targets for Potential Anti-Obesity Drugs. Mini-Reviews in Medicinal Chemistry, 2007, 7, 11-19.	1.1	7
151	<i>In Vitro</i> Chronic Administration of ERbeta Selective Ligands and Prostate Cancer Cell Growth: Hypotheses on the Selective Role of 3beta-Adiol in AR-Positive RV1 Cells. BioMed Research International, 2014, 2014, 1-14.	0.9	7
152	Gender difference in lipoprotein(a) concentration as a predictor of coronary revascularization in patients with known coronary artery disease. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2021, 1866, 158869.	1.2	7
153	Effects of Statins on Renin–Angiotensin System. Journal of Cardiovascular Development and Disease, 2021, 8, 80.	0.8	7
154	Impact of Atorvastatin on Skeletal Muscle Mitochondrial Activity, Locomotion and Axonal Excitability—Evidence from ApoE-/- Mice. International Journal of Molecular Sciences, 2022, 23, 5415.	1.8	7
155	1280 DIETARY IRON OVERLOAD INDUCES VISCERAL ADIPOSE TISSUE INSULIN RESISTANCE ASSOCIATED WITH HYPER-RESISTINEMIA, AND SYNERGIZES WITH OBESITY AND FATTY LIVER IN INDUCING SYSTEMIC INSULIN RESISTANCE. Journal of Hepatology, 2011, 54, S505.	1.8	6
156	Increased circulating adiponectin in males with chronic HCV hepatitis. European Journal of Internal Medicine, 2015, 26, 635-639.	1.0	6
157	Can we further optimize statin therapy to increase tolerability?. Expert Opinion on Drug Discovery, 2019, 14, 843-847.	2.5	6
158	Relationship between Circulating PCSK9 and Markers of Subclinical Atherosclerosisâ€"The IMPROVE Study. Biomedicines, 2021, 9, 841.	1.4	6
159	New players in the treatment of hypercholesterolaemia: focus on bempedoic acid and inclisiran. European Heart Journal Supplements, 2021, 23, E59-E62.	0.0	6
160	Cholinergic regulation of neuropeptide Y synthesis and release in human neuroblastoma cells. Peptides, 2008, 29, 491-495.	1.2	5
161	Impact of bariatric surgery-induced weight loss on circulating PCSK9 levels in obese patients. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 2372-2378.	1.1	5
162	PCSK9 as a new player in cancer: New opportunity or red herring?. Current Medicinal Chemistry, 2021, 28, .	1.2	5

#	Article	IF	CITATIONS
163	HDLâ€mediated reduction of cholesterol content inhibits the proliferation of prostate cancer cells induced by LDL: Role of ABCA1 and proteasome inhibition. BioFactors, 2022, 48, 707-717.	2.6	5
164	Residual vascular risk in diabetes $\hat{a}\in$ "Will the SPPARM alpha concept hold the key?. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2019, 13, 2723-2725.	1.8	4
165	Left main coronary wall thickness correlates with the carotid intima media thickness and may provide a new marker of cardiovascular risk. European Journal of Preventive Cardiology, 2019, 26, 1001-1004.	0.8	4
166	PCSK9 Induces Rat Smooth Muscle Cell Proliferation and Counteracts the Pleiotropic Effects of Simvastatin. International Journal of Molecular Sciences, 2021, 22, 4114.	1.8	4
167	Impact of Phyllantus niruri and Lactobacillus amylovorus SGL 14 in a mouse model of dietary hyperoxaluria. Beneficial Microbes, 2020, 11, 547-559.	1.0	3
168	Role of the energy sensor adenosine monophosphate-activated protein kinase in the regulation of immature gonadotropin-releasing hormone neuron migration. Journal of Endocrinological Investigation, 2011, 34, e362-8.	1.8	3
169	Brain-Derived Neurotrophic Factor and Extracellular Vesicle-Derived miRNAs in an Italian Cohort of Individuals With Obesity: A Key to Explain the Link Between Depression and Atherothrombosis. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	3
170	PCSK9 in HIV infection: New opportunity or red herring?. Atherosclerosis, 2019, 284, 216-217.	0.4	2
171	Non-alcoholic fatty liver disease and cardiovascular disease: A still debated liaison. European Journal of Preventive Cardiology, 2020, 27, 1056-1058.	0.8	2
172	Cyclase-associated protein 2 (CAP2) controls MRTF-A localization and SRF activity in mouse embryonic fibroblasts. Scientific Reports, 2021, 11, 4789.	1.6	2
173	Molecular Aspects of Adipokine-Bone Interactions. Current Molecular Medicine, 2010, 10, 522-532.	0.6	1
174	F-17 Dietary iron overload induces visceral adipose tissue insulin resistance and hyper-resistinemia, and synergizes with obesity and fatty liver in inducing systemic insulin resistance. Digestive and Liver Disease, 2011, 43, S97.	0.4	1
175	872 ADIPONECTIN IN NONALCOHOLIC FATTY LIVER DISEASE: CORRELATION WITH LIVER DAMAGE AND PNPLA3 GENOTYPE. Journal of Hepatology, 2011, 54, S347-S348.	1.8	1
176	TNF-alpha induces proprotein convertase subtilisin kexin type 9 (PCSK9) expression in hepatic HepG2 cell line in a SOCS-3-dependent manner. Atherosclerosis, 2016, 252, e197-e198.	0.4	1
177	Soya-enriched mixed diet significantly improves cardiovascular and metabolic risk factors: A randomized controlled trial. Atherosclerosis, 2016, 252, e210.	0.4	1
178	Inherited atherogenic dyslipidemias: are they correctly reported?. European Journal of Preventive Cardiology, 2020, , 2047487320930308.	0.8	1
179	Evaluation of Transthoracic Echocardiography in the Assessment of Atherosclerosis of the Left Main Coronary Artery: Comparison with Optical Frequency Domain Imaging (a Pilot Study). Journal of Clinical Medicine, 2021, 10, 256.	1.0	1
180	TM6SF2/PNPLA3/MBOAT7 loss-of-function genetic variants impact on NAFLD development and progression both in patients and in in vitro models. Digestive and Liver Disease, 2021, 53, S27-S28.	0.4	1

#	Article	IF	CITATIONS
181	T-11 Adiponectin in nonalcoholic fatty liver disease: Correlation with liver damage and PNPLA3 genotype. Digestive and Liver Disease, 2011, 43, S80.	0.4	0
182	NPY (neuropeptide Y). Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2011, , .	0.1	0
183	NPY1R (neuropeptide Y receptor Y1). Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2011, , .	0.1	O
184	STAT3 inhibition induces PCSK9 in hepatic cell line: possible involvement in hypertriglyceridemia associated with insulin resistance. Atherosclerosis, 2015, 241, e46-e47.	0.4	0
185	Liver fat accumulation is associated with circulating PCSK9 levels. Digestive and Liver Disease, 2015, 47, e230.	0.4	0
186	Gold nanocages for imaging and therapy of prostate cancer cells. Proceedings of SPIE, 2016, , .	0.8	0
187	Role of PCSK9 (proprotein convertase subtilisin/kexin type 9) in obesity and metabolic syndrome: Beyond LDLR targeting. Atherosclerosis, 2016, 252, e223.	0.4	0
188	Circulating PCSK9 Levels are Associated with the Hepatic Fat in Non-Alcoholic Fatty Liver Disease. Journal of Hepatology, 2016, 64, S492.	1.8	0
189	Influence of PCSK9 on biological behavior of mouse smooth muscle cells. Atherosclerosis, 2017, 263, e63.	0.4	0
190	Role of PCSK9 (proprotein convertase subtilisin/kexin type 9) beyond LDLR targeting: Focus on glucose metabolism. Atherosclerosis, 2017, 263, e102.	0.4	0
191	Circulating levels of PCSK9 and arterial stiffness in a large population sample: Data from the brisighella heart study. Atherosclerosis, 2017, 263, e105-e106.	0.4	0
192	Leptin and resistin affect PCSK9 expression via STAT3 involvement. Atherosclerosis, 2017, 263, e70-e71.	0.4	0
193	[OP.1A.10] CIRCULATING LEVELS OF PCSK9 AND ARTERIAL STIFFNESS IN A LARGE POPULATION SAMPLE. Journal of Hypertension, 2017, 35, e3-e4.	0.3	0
194	Plasma PCSK9 levels and lipoprotein distribution are preserved in patients with severe hypoalphalipoproteinemia. Atherosclerosis, 2017, 263, e91.	0.4	0
195	PCSK9 induces a pro-inflammatory response in macrophages. Atherosclerosis, 2017, 263, e11.	0.4	0
196	The PCSK9/LDLR axis impacts insulin secretion and glucose response. Atherosclerosis, 2018, 275, e55.	0.4	0
197	Leptin and resistin affect PCSK9 expression: In vitro and in vivo evidence. Atherosclerosis, 2018, 275, e18.	0.4	0
198	PCSK9 Deficiency Reduces Insulin Secretion and Promotes Glucose Intolerance: the Role of the LDL Receptor. Atherosclerosis Supplements, 2018, 32, 21.	1.2	0

#	Article	IF	CITATIONS
199	Role Of Pcsk9 On Pancreatic Function And Insulin Release; Evidence From Mice Models. Atherosclerosis, 2019, 287, e44-e45.	0.4	0
200	Sex hormones therapy differentially modulates HDL function in transgender individuals. Atherosclerosis, 2020, 315, e10.	0.4	0
201	Effects of a nutraceutical combination (bifidobacterium longum BB536, red yeast rice extract) on cholesterol metabolism to oxysterols: a randomized, double-blind, placebo-controlled study in moderate hypercholesterolaemia. Atherosclerosis, 2020, 315, e272.	0.4	0
202	Role of MCT1 lactate transporter in t lymphocytes activation and function during obesity. Atherosclerosis, 2020, 315, e98.	0.4	0
203	Overexpression of PCSK9 in human smooth muscle cells renders extracellular vesicles atherogenic Atherosclerosis, 2021, 331, e67.	0.4	0
204	Cardiovascular complications of COVID-19: toward better understanding, diagnosis, monitoring and management. Expert Review of Anti-Infective Therapy, 2021, , 1-2.	2.0	0
205	MCT1 lactate transporter deletion in T lymphocytes improves adipose tissue homeostasis during obesity. Atherosclerosis, 2021, 331, e175.	0.4	0
206	Hormone therapy impacts on HDL-CEC but not on HDL subclasses and serum loading capacity: A cohort of transgender individuals Atherosclerosis, 2021, 331, e128-e129.	0.4	0
207	Efficacy and safety of a nutraceutical with probiotic and red yeast rice extract in patients with moderate hypercholesterolemia: A randomized, double-blind, placebo-controlled study. Atherosclerosis, 2017, 263, e109.	0.4	0
208	Male patients with hypogonadism have an impaired lipoprotein function. Endocrine Abstracts, 0, , .	0.0	0
209	SAT-LB92 Sex Hormones Therapy Differentially Modulates HDL Function in Transgender Individuals. Journal of the Endocrine Society, 2020, 4, .	0.1	0
210	Angiotensin-converting enzyme 2 (ACE2): New opportunity or red herring?., 2020, 02,.		0
211	Monocarboxylate Transporter 1 Deficiency Impacts CD8 ⁺ T Lymphocytes Proliferation and Recruitment to Adipose Tissue During Obesity. SSRN Electronic Journal, 0, , .	0.4	O